Mustang Bio

About:

Mustang Bio is a clinical-stage biopharmaceutical company .

Top Investors: Runway Growth Capital, Horizon Technology Finance, National Institutes of Health, California Institute for Regenerative Medicine

Description:

Mustang Bio is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient's own immune system to eliminate cancer cells. The products under development are - CD123, CD20, and CS1.

Total Funding Amount:

$219M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

New York, New York, United States

Founded Date:

2015-01-01

Contact Email:

info(AT)mustangbio.com

Founders:

Michael S. Weiss Weiss

Number of Employees:

51-100

Last Funding Date:

2024-10-24

IPO Status:

Public

Industries: